CIRM Funded Clinical Trials

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Disease Area:	Sarcoma
Investigator:	Theodore Nowicki
Institution:	University of California, Los Angeles
CIRM Grant:	CLIN2-11380
Award Value:	$4,693,839
Trial Sponsor:	University of California, Los Angeles
Trial Stage:	Phase 1
Trial Status:	Recruiting
Targeted Enrollment:	12
ClinicalTrials.gov ID:	NCT03240861



Theodore Nowicki

Details:
This is a treatment for patients with sarcomas and other advanced solid tumors. In 2018 alone, an estimated 13,040 people were diagnosed with soft tissue sarcoma (STS) in the United States, with approximately 5,150 deaths. Standard of care treatment for sarcomas typically consists of surgery, radiation, and chemotherapy, but patients with late stage or recurring tumor growth have few options.

Dr. Nowicki and his team will genetically modify peripheral blood stem cells (PBSCs) and peripheral blood monocular cells (PBMCs) to target these solid tumors. The gene modified stem cells, which have the ability to self-renew, provide the potential for durable effect.

Design:
This is a Phase I clinical trial

Goal:
To evaluate the safety and feasibility of administering NY-ESO-1 TCR (T cell receptor)engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after a myeloablative conditioning regimen to treat patients with cancer that has spread to other parts of the body.